This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Entasis Therapeutics Holdings Future Growth
Future criteria checks 2/6
Key information
52.3%
Earnings growth rate
52.0%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 67.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16
Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19Entasis Therapeutics shares rise after lining up ETX0462 poster presentation
Jun 18What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 32 | -35 | -42 | -38 | 2 |
| 12/31/2023 | 8 | -60 | N/A | -53 | 2 |
| 12/31/2022 | N/A | -61 | N/A | -56 | 3 |
| 3/31/2022 | N/A | -52 | -47 | -47 | N/A |
| 12/31/2021 | N/A | -47 | -43 | -43 | N/A |
| 9/30/2021 | N/A | -46 | -38 | -38 | N/A |
| 6/30/2021 | N/A | -45 | -39 | -39 | N/A |
| 3/31/2021 | N/A | -46 | -42 | -42 | N/A |
| 12/31/2020 | N/A | -50 | -45 | -45 | N/A |
| 9/30/2020 | N/A | -54 | -46 | -46 | N/A |
| 6/30/2020 | 7 | -46 | -43 | -43 | N/A |
| 3/31/2020 | 7 | -46 | -48 | -48 | N/A |
| 12/31/2019 | 7 | -44 | -45 | -45 | N/A |
| 9/30/2019 | 7 | -38 | -45 | -45 | N/A |
| 6/30/2019 | N/A | -52 | -43 | -43 | N/A |
| 3/31/2019 | 5 | -44 | -34 | -33 | N/A |
| 12/31/2018 | 5 | -42 | -36 | -36 | N/A |
| 9/30/2018 | 5 | -43 | -34 | -33 | N/A |
| 6/30/2018 | 5 | -34 | -33 | -33 | N/A |
| 3/31/2018 | N/A | -35 | -34 | -34 | N/A |
| 12/31/2017 | N/A | -30 | -27 | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ETTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ETTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ETTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ETTX's revenue (67.6% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: ETTX's revenue (67.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ETTX's Return on Equity is forecast to be high in 3 years time